Cattadori G, Di Marco S, Farina S, Limongelli G, Monda E, Badagliacca R, Papa S, Tricarico L, Correale M. Beta-blockers in heart failure prognosis: Lessons learned by MECKI Score Group papers.
Eur J Prev Cardiol 2020;
27:65-71. [PMID:
33238743 PMCID:
PMC7691627 DOI:
10.1177/2047487320951109]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Heart failure is a complex syndrome affecting several organs including kidney,
lungs, liver, brain muscles and sympathetic system. Each of these organs might
contribute to its severity and prognosis. The prognosis assessment is critical
for a correct heart failure management. It has already been demonstrated that a
single parameter is weaker for prognosis than different parameters combined. The
Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI)
score has been built and validated for heart failure with reduced ejection
fraction (HFrEF) patients by considering cardiopulmonary exercise test data
combined with clinical, laboratory and echocardiographic measurements. The
betablockers treatment is a milestone in the HFrEF management. In the MECKI
score database, the association of betablockers treatment with outcome has been
investigated in different settings.
Collapse